Cardioprotection: Emerging pharmacotherapy

R. J. Gumina, A. Jahangir, G. J. Gross, Andre Terzic

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

By the year 2020, it is predicted that acute coronary occlusion will be the major cause of death in the world. Recent advances in reperfusion therapy have substantially improved survival of patients with acute coronary syndromes. While early reperfusion reduces mortality, a time limitation exists with regard to myocardial salvage. In fact, the major limiting factor in further improving survival of patients with myocardial ischaemia is the susceptibility of the cardiomyocyte to ischaemic insult and lethal cell injury. Over the last decade substantial progress has been made in our understanding of the fundamental mechanisms of ischaemia/reperfusion injury. From this work novel means which limit or delay myocyte death have emerged and are currently under development as therapeutic candidates for the management of acute coronary syndromes. This report examines cardioprotective mechanisms and reviews clinical evidence for myocardial protective therapies.

Original languageEnglish (US)
Pages (from-to)739-752
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume2
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Acute Coronary Syndrome
Drug Therapy
Reperfusion
Survival
Coronary Occlusion
Reperfusion Injury
Cardiac Myocytes
Muscle Cells
Myocardial Ischemia
Cause of Death
Therapeutics
Mortality
Wounds and Injuries

Keywords

  • Adenosine
  • Antineutrophils
  • Cardioprotection
  • Clinical trials
  • Magnesium
  • Myocardial infarction
  • Opioids
  • Potassium channel openers
  • Sodium-hydrogen exchanger inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Cardioprotection : Emerging pharmacotherapy. / Gumina, R. J.; Jahangir, A.; Gross, G. J.; Terzic, Andre.

In: Expert Opinion on Pharmacotherapy, Vol. 2, No. 5, 2001, p. 739-752.

Research output: Contribution to journalArticle

Gumina, R. J. ; Jahangir, A. ; Gross, G. J. ; Terzic, Andre. / Cardioprotection : Emerging pharmacotherapy. In: Expert Opinion on Pharmacotherapy. 2001 ; Vol. 2, No. 5. pp. 739-752.
@article{3550f9ebead348c0a34cdccad41a4f3e,
title = "Cardioprotection: Emerging pharmacotherapy",
abstract = "By the year 2020, it is predicted that acute coronary occlusion will be the major cause of death in the world. Recent advances in reperfusion therapy have substantially improved survival of patients with acute coronary syndromes. While early reperfusion reduces mortality, a time limitation exists with regard to myocardial salvage. In fact, the major limiting factor in further improving survival of patients with myocardial ischaemia is the susceptibility of the cardiomyocyte to ischaemic insult and lethal cell injury. Over the last decade substantial progress has been made in our understanding of the fundamental mechanisms of ischaemia/reperfusion injury. From this work novel means which limit or delay myocyte death have emerged and are currently under development as therapeutic candidates for the management of acute coronary syndromes. This report examines cardioprotective mechanisms and reviews clinical evidence for myocardial protective therapies.",
keywords = "Adenosine, Antineutrophils, Cardioprotection, Clinical trials, Magnesium, Myocardial infarction, Opioids, Potassium channel openers, Sodium-hydrogen exchanger inhibitors",
author = "Gumina, {R. J.} and A. Jahangir and Gross, {G. J.} and Andre Terzic",
year = "2001",
doi = "10.1517/14656566.2.5.739",
language = "English (US)",
volume = "2",
pages = "739--752",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Cardioprotection

T2 - Emerging pharmacotherapy

AU - Gumina, R. J.

AU - Jahangir, A.

AU - Gross, G. J.

AU - Terzic, Andre

PY - 2001

Y1 - 2001

N2 - By the year 2020, it is predicted that acute coronary occlusion will be the major cause of death in the world. Recent advances in reperfusion therapy have substantially improved survival of patients with acute coronary syndromes. While early reperfusion reduces mortality, a time limitation exists with regard to myocardial salvage. In fact, the major limiting factor in further improving survival of patients with myocardial ischaemia is the susceptibility of the cardiomyocyte to ischaemic insult and lethal cell injury. Over the last decade substantial progress has been made in our understanding of the fundamental mechanisms of ischaemia/reperfusion injury. From this work novel means which limit or delay myocyte death have emerged and are currently under development as therapeutic candidates for the management of acute coronary syndromes. This report examines cardioprotective mechanisms and reviews clinical evidence for myocardial protective therapies.

AB - By the year 2020, it is predicted that acute coronary occlusion will be the major cause of death in the world. Recent advances in reperfusion therapy have substantially improved survival of patients with acute coronary syndromes. While early reperfusion reduces mortality, a time limitation exists with regard to myocardial salvage. In fact, the major limiting factor in further improving survival of patients with myocardial ischaemia is the susceptibility of the cardiomyocyte to ischaemic insult and lethal cell injury. Over the last decade substantial progress has been made in our understanding of the fundamental mechanisms of ischaemia/reperfusion injury. From this work novel means which limit or delay myocyte death have emerged and are currently under development as therapeutic candidates for the management of acute coronary syndromes. This report examines cardioprotective mechanisms and reviews clinical evidence for myocardial protective therapies.

KW - Adenosine

KW - Antineutrophils

KW - Cardioprotection

KW - Clinical trials

KW - Magnesium

KW - Myocardial infarction

KW - Opioids

KW - Potassium channel openers

KW - Sodium-hydrogen exchanger inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0034876552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034876552&partnerID=8YFLogxK

U2 - 10.1517/14656566.2.5.739

DO - 10.1517/14656566.2.5.739

M3 - Article

C2 - 11336619

AN - SCOPUS:0034876552

VL - 2

SP - 739

EP - 752

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -